Nitisinone Treatment Affects Biomarkers of Bone and Cartilage Remodelling in Alkaptonuria Patients
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241310996 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Federica Genovese und 8 weiteren Autor:innen. Beteiligte Einrichtung: Nordic Bioscience A/S, 2730 Herlev, Denmark. Hauptthemen laut MEDLINE: Alkaptonuria. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Commission.
Abstract (Originalsprache)
Nitisinone has been approved for treatment of alkaptonuria (AKU). Non-invasive biomarkers of joint tissue remodelling could aid in understanding the molecular changes in AKU pathogenesis and how these can be affected by treatment. Serological and urinary biomarkers of type I collagen and II collagen in AKU were investigated in patients enrolled in the randomized SONIA 2 (NCT01916382) clinical study at baseline and yearly until the end of the study (Year 4). The trajectories of the biomarkers over time were observed. After treatment with nitisinone, the biomarkers of type I collagen remodelling increased at Year 1 (19% and 40% increase in CTX-I and PRO-C1, respectively), which was potentially reflected in the higher degree of mobility seen following treatment. The biomarkers of type II collagen remodelling decreased over time in the nitisinone group: C2M showed a 9.7% decline at Year 1, and levels then remained stable over the following visits; CTX-II showed a 26% decline at Year 3 and 4 in the nitisinone-treated patients. Nitisinone treatment induced changes in biomarkers of bone and cartilage remodelling. These biomarkers can aid patient management and deepen our knowledge of the molecular mechanisms of this rare disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nordic Bioscience A/S, 2730 Herlev, Denmark.
- Department of Clinical Biochemistry and Metabolic Medicine, Liverpool Clinical Laboratories, Liverpool University Hospitals NHS Foundation Trust, Liverpool L69 3BX, UK.
- Garriguella AB, 179 62 Ekerö, Sweden.
- OnPoint Science AB, 118 49 Stockholm, Sweden.
- Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool L69 3BX, UK.
ORCID-Profile: Federica Genovese, Anne-Christine Bay-Jensen, Anna M Milan, Mattias Rudebeck
Förderung
- European Commission
Zitieren
APA
Genovese, F., Frederiksen, P., Bay-Jensen, A. C., Karsdal, M. A., Milan, A. M., Olsson, B., Rudebeck, M., Gallagher, J. A., & Ranganath, L. R. (2023). Nitisinone Treatment Affects Biomarkers of Bone and Cartilage Remodelling in Alkaptonuria Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241310996
Vancouver
Genovese F, Frederiksen P, Bay-Jensen AC, Karsdal MA, Milan AM, Olsson B, et al. Nitisinone Treatment Affects Biomarkers of Bone and Cartilage Remodelling in Alkaptonuria Patients. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241310996
BibTeX
@article{Genovese2023,
author = {Genovese, Federica and Frederiksen, Peder and Bay-Jensen, Anne-Christine and Karsdal, Morten A and Milan, Anna M and Olsson, Birgitta and Rudebeck, Mattias and Gallagher, James A and Ranganath, Lakshminarayan R},
title = {Nitisinone Treatment Affects Biomarkers of Bone and Cartilage Remodelling in Alkaptonuria Patients},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241310996}
}
EUVIMED